The estimated Net Worth of Peter Maag is at least $47 Milion dollars as of 20 August 2024. Peter Maag owns over 35,552 units of Caredx Inc stock worth over $9,415,585 and over the last 10 years he sold CDNA stock worth over $28,705,630. In addition, he makes $8,855,740 as Executive Chairman of the Board of Directors at Caredx Inc.
Peter has made over 62 trades of the Caredx Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 35,552 units of CDNA stock worth $1,174,638 on 20 August 2024.
The largest trade he's ever made was exercising 113,421 units of Caredx Inc stock on 10 May 2021 worth over $1,319,086. On average, Peter trades about 14,915 units every 36 days since 2014. As of 20 August 2024 he still owns at least 330,024 units of Caredx Inc stock.
You can see the complete history of Peter Maag stock trades at the bottom of the page.
Dr. Peter Maag Ph.D. serves as Executive Chairman of the Board of Directors of the Company. is Chief Executive Officer and Director of the Company. Dr. Maag has served as our Chief Executive Officer since October 2012 and as a member of our Board of Directors since November 2012. Dr. Maag also served as our President from October 2012 until November 2018. Prior to joining the Company, Dr. Maag held numerous positions with increasing responsibility at Novartis International AG, a global healthcare company from September 2001 to April 2012, including Global Head of Novartis Diagnostics, a business unit of Novartis A.G., from 2009 to 2012. Dr. Maag also served as Country President for Novartis Pharma AG in Germany from 2006 to 2008, Country President for Novartis’ Korea operations from 2003 to 2005, and the Head of Strategy for the pharmaceutical division of Novartis A.G. from 2001 to 2002. Dr. Maag also worked at McKinsey & Company, focusing on healthcare and globalization from 1995 to 2001. Besides supporting various healthcare and tech companies in their growth efforts, Dr. Maag also holds a board position at Phoenix Pharma SE and serves on the board of Personalized Medicine Coalition in Washington D.C. Dr. Maag studied pharmaceutical sciences at the University of Heidelberg and University of London and received his Ph.D. from the University of Berlin, Germany.
As the Executive Chairman of the Board of Directors of Caredx Inc, the total compensation of Peter Maag at Caredx Inc is $8,855,740. There are no executives at Caredx Inc getting paid more.
Peter Maag is 53, he's been the Executive Chairman of the Board of Directors of Caredx Inc since 2020. There are 6 older and 9 younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
Peter's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, BRISBANE, CA, 94005.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon a Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: